Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2018

View Archived Issues

Inhibiting mitochondrial RTK is breast cancer target

Protein-tyrosine kinase 2 identified as a therapeutic target for Kawasaki disease

Colorectal cancer stem cells are made, not born: study

Kineta starts first-in-human study of LHF-535

Proof-of-concept data presented from PHYOX phase I study of DCR-PHXC in primary hyperoxaluria

LEAPS rheumatoid arthritis vaccine selected for commercialization accelerator program

PLAG1 overexpression induces Wilms tumor formation and correlates with early relapse in patients

Phase III study of NeoCart in patients with knee cartilage damage does not meet the primary endpoint

GT-73 demonstrates efficacy in various in vivo models

Phase I/II results with pegzilarginase in arginase deficiency support upcoming pivotal trial

CB-59 and CB-81, two small-molecule tau aggregation inhibitors with CNS drug-like properties

Phase I/II interim data on QR-110 in LCA10 support progression to phase II/III

Summit Therapeutics names lead clinical candidate for gonorrhea

Daewoong Pharmaceutical patents EPRS inhibitors

Argenx initiates phase III trial of efgartigimod in generalized myasthenia gravis

Enanta Pharmaceuticals divulges new NR1H4 agonists

OncoArendi Therapeutics presents new AMCase and CHIT1 dual inhibitors for lung diseases

Adocia reports phase I data on BioChaperone Pramlintide Insulin in type 1 diabetes

AIC-649 stimulates the immune system of patients with chronic HBV in phase I trial

DSMB recommends continuation of phase IIb study of OPT-302 in wet AMD

Phoenix PharmaLabs receives support to study PPL-103 for cocaine addiction

Phase III study of PET imaging agent flortaucipir F 18 meets primary endpoints

Phase II TORTUGA trial of filgotinib in ankylosing spondylitis meets primary efficacy endpoint

Poseida notes data from ongoing phase I study of P-BCMA-101 in relapsed/refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...